Results 181 to 190 of about 59,298 (301)
New Insights into Neuromuscular Junction Biology: Evidence from Human and Animal Research. [PDF]
Liang Z, Chen X, Nourbakhsh M.
europepmc +1 more source
ABSTRACT Urinary dysfunction has been reported in association with myasthenic syndromes, including myasthenia gravis (MG), Lambert–Eaton myasthenic syndrome (LEMS), and congenital myasthenic syndromes (CMS), but evidence regarding its prevalence, clinical impact, pathophysiology, and management remains limited.
Julia M. Augustin +13 more
wiley +1 more source
Monitoring of Neuromuscular Junction.
D Padmaja, Srinivas Mantha
doaj
Neuromuscular junction innervation and motor function are preserved by restoring muscarinic signaling in perisynaptic glia in ALS. [PDF]
Tremblay E +6 more
europepmc +1 more source
Targeted Muscle Reinnervation for Intuitive Prosthetic Control
ABSTRACT The convergence of medical and technological advances has led to a substantial expansion of therapeutic approaches for patients with limb amputations. Targeted muscle reinnervation (TMR) is one of the strategies to improve control of bionic arms and has been applied for more than two decades. Through surgical rewiring of the nerves responsible
Nitay Maile +5 more
wiley +1 more source
The chaperonin TRiC component Cct3 is required for axonal transport, myelination, and neuromuscular junction refinement. [PDF]
Zhang X +7 more
europepmc +1 more source
ABSTRACT Introduction/Aims Quantitative muscle ultrasound (QMUS) is a validated technique for assessing muscle pathology, yet its role in disorders primarily affecting the neuromuscular junction (NMJ) remains unclear. This pilot study aimed to explore whether QMUS is associated with structural muscle changes in patients with acquired or genetic NMJ ...
Artor Pogosean +3 more
wiley +1 more source
Age-Dependent Regulation of Acetylcholine Release at the Neuromuscular Junction Mediated by GABA. [PDF]
Nevsky E +5 more
europepmc +1 more source
ABSTRACT Background & Aims Neurogenic lower urinary tract dysfunction (NLUTD) can produce bothersome urinary symptoms, impact quality of life, and in some cases, lead to deterioration of upper urinary tract function. Intradetrusor injection of onabotulinumtoxin‐A (BoNT‐A) is approved for NLUTD in patients who have an inadequate response to or ...
Shirley L. Wang +2 more
wiley +1 more source
Systemic AAV9 Gene Therapy Mitigates Neuromuscular Junction Degeneration and Muscle Atrophy in a Mouse Model of CLN1 Disease. [PDF]
Ziółkowska EA +8 more
europepmc +1 more source

